Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen

Contraception

Volumn 80, Issue 3, 2009, Pages 245-253

  Archer, David F ^a   Kovalevsky, George ^a   Ballagh, Susan A ^a   Grubb, Gary S ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

Continuous oral contraception; Ethinyl estradiol; Levonorgestrel; Ovarian follicle suppression; Ovulation inhibition and return; Ultrasound

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; OPEN STUDY; OVARY FUNCTION; OVULATION INHIBITION; PROGESTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, HORMONAL; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; OVARIAN FOLLICLE; OVULATION INHIBITION; PROGESTERONE; YOUNG ADULT;

EID: 68749095069     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.03.006     Document Type: Article

References (16)

1. Kuntz A.M. Menstruation: choosing whether and when. Contraception 62 (2000) 277-284
2. Archer D.F. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 74 (2006) 359-366
3. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
4. Miller L., and Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 101 (2003) 653-661
5. Archer D.F., Jensen J.T., Johnson J.V., Borisute H., Grubb G.S., and Constantine G.D. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 74 (2006) 439-445
6. Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72 (1999) 115-120
7. Birtch R.L., Olatunbosun O.A., and Pierson R.A. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception 73 (2006) 235-243
8. Schlaff W.D., Lynch A.M., Hughes H.D., Cedars M.I., and Smith D.L. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am J Obstet Gynecol 190 (2004) 943-951
9. Hoogland H.J., and Skouby S.O. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 47 (1993) 583-590
10. Belsey E.M. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Methods of contraception. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Adv Contracept 7 (1991) 257-270
11. Craig L.B., Miller L., and Criniti A. Rapid resumption of ovulation and menstruation following continuous use of the combination oral contraceptive. Fertil Steril 83 suppl 2 (2005) S16 [Abstract].
12. Davis A.R., Kroll R., Soltes B., Zhang N., Grubb G.S., and Constantine G.D. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 89 (2008) 1059-1063
13. Greco T., Graham C.A., Bancroft J., Tanner A., and Doll H.A. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 76 (2007) 8-17
14. Coenen C.M., Thomas C.M., Borm G.F., Hollanders J.M., and Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 53 (1996) 171-176
15. Wiegratz I., Jung-Hoffmann C., and Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 51 (1995) 341-346
16. Palatsi R., Reinila M., and Kivinen S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol 66 (1986) 225-230